Table 3 Cox regression analysis on the association of laboratory results with disease activity in follow-up visits. Results of Cox regression analysis were shown in this table, which analyzed the association of ESR, hsCRP, IL-6, and TNFα with inactive disease or relapse in follow-up visits among 354 Takayasu’s arteritis patients who were followed-up
Disease activity in follow-up visits | p value | HR (95% CI) | Positive predictive value | Negative predictive value | |||
|---|---|---|---|---|---|---|---|
Inactive | Active | (95% CI) | (95% CI) | ||||
152 patients in active group at baseline | |||||||
Number of patients | 120 | 32 | |||||
ESR | (≤ 20 mm/1st hour) | 106 (86.2%) | 17 (13.8%) | < 0.001 | 1.00 | 53.6% (33.9–72.5%) | 86.2% (78.8–91.7%) |
(> 20 mm/1st hour) | 13 (46.4%) | 15 (53.6%) | 0.32 (0.18–0.58) | ||||
hsCRP | (≤8 mg/L) | 84 (91.3%) | 8 (8.7%) | < 0.001 | 1.00 | 42.7% (29.7-56. 8%) | 91.3% (83.6–96.2%) |
(> 8 mg/L) | 32 (57.1%) | 24 (42.9%) | 0.45 (0.30–0.68) | ||||
IL-6 | (≤ 5.9 pg/ml) | 65 (87.8%) | 9 (12.2%) | 0.006 | 1.00 | 33.3% (19.6–49.6%) | 87.8% (78.2–94.3%) |
(> 5.9 pg/ml) | 28 (66.7%) | 14 (33.3%) | 0.54 (0.34–0.84) | ||||
TNFα | (≤ 8.1 pg/ml) | 56 (76.7%) | 17 (23.3%) | 0.25 | 1.00 | 14.3% (5.4–28.5%) | 76.7% (65.4–85.8%) |
(> 8.1 pg/ml) | 36 (85.7%) | 6 (14.3%) | 1.31 (0.86–2.00) | ||||
202 patients in inactive group at baseline | |||||||
Number of patients | 96 | 106 | |||||
ESR | (≤ 20 mm/1sthr) | 87 (57.3%) | 65 (42.8%) | < 0.001 | 1.00 | 80.9% (66.7–90.9%) | 57.2% (49.0–65.2%) |
(> 20 mm/1sthr) | 9 (19.2%) | 38 (80.9%) | 2.11 (1.41–3.16) | ||||
hsCRP | (≤ 8 mg/L) | 84 (56.8%) | 64 (43.3%) | < 0.001 | 1.00 | 82.2% (68.0–92.0%) | 56.8% (48.4–64.9%) |
(> 8 mg/L) | 8 (17.8%) | 37 (82.2%) | 2.13 (1.42–3.20) | ||||
IL-6 | (≤5.9 pg/ml) | 80 (61.1%) | 51 (38.9%) | < 0.001 | 1.00 | 78.1% (62.4–89.4%) | 61.1% (52.2–69.5%) |
(> 5.9 pg/ml) | 9 (22.0%) | 32 (78.1%) | 2.50 (1.60–3.91) | ||||
TNFα | (≤8.1 pg/ml) | 65 (63.1%) | 38 (36.9%) | < 0.001 | 1.00 | 65.2% (52.4–76.5%) | 63.1% (53.0–72.4%) |
(> 8.1 pg/ml) | 23 (34.9%) | 43 (65.2%) | 2.65 (1.69–4.15) | ||||